Built by the operators who scaled healthcare cybersecurity.
Valentra Labs turns hard-won program experience into an operating layer for cybersecurity teams. Our credibility is cited operator history — not a wall of customer logos.
Design partners
Valentra Labs is shaping Valentra Nexus with a founding cohort of design partners. Here is where that program stands today.
EnrollingDesign partners onboarding now
Updated
Operator history
The credibility behind Valentra Labs is a track record, stated plainly and dated — not a marketing claim.
Scaled Clearwater's healthcare cybersecurity practice from ~$4M to $47M+ ARR; Best in KLAS.
Jonathan Kaeuper
Co-Founder
SME and advisor on Clearwater's IRM|Pro.
The Decision Packet
What the program produces: a board-ready packet that carries the situation, options, recommendation, evidence, and approval chain.
Decision Packet · v1.0
Q2 2026 — Crown-Jewel Risk Disposition
pkt_2026-04-17_a3f8e1·
Situation
Q2 program review covers the crown-jewel ePHI store and its supporting control envelope. 487 endpoints catalogued across three network segments; 12 unsanctioned SaaS surfaces detected by the shadow-IT scan. Continuous monitoring posture is operating; the residual question is risk acceptance for two compensating-control gaps surfaced this cycle.
Risk & Impact
14 critical findings scored against the revenue-at-risk model. Two compensating gaps (vendor-SOC-2 attestation lapse + patch-cycle #38 awaiting CAB sign-off) carry residual risk of $1.4M in unmitigated regulatory exposure if a HITRUST audit lands before remediation closes. Patient-data confidentiality remains the load-bearing impact dimension.
Options
Accept residual risk through Q3, with quarterly board re-review.
Accelerate remediation by re-prioritizing the patch cycle ahead of the planned Q3 platform migration (cost: 2 engineer-weeks).
Transfer risk via expanded cyber-insurance rider (cost: $48K/yr premium delta; coverage gap on ePHI exfiltration remains).
Recommendation
Pursue Option 2 — accelerate remediation. The 2 engineer-weeks of effort cost is recoverable in Q3; the residual exposure is asymmetric (regulatory floor of $1.4M vs. ~$120K labor delta). Document the patch-cycle re-prioritization as a logged decision with the program owner; close the SOC-2 attestation gap via vendor outreach in the same window. Insurance rider deferred to Q4 review.
Evidence
Twelve evidence artifacts back the recommendation — asset inventory, control mapping, vendor SOC-2 status, residual-risk model, patch-cycle telemetry, and the prior packet's audit trail. One control attestation is overridden with a documented compensating-control narrative; two vendor attestations are pending the Q2 refresh window.
Overridden per compensating-control narrative — see attached
Penetration test report — Q1 follow-up
#a5b6c7d8
stale
—
Prior packet audit trail — pkt_2026-01-09_b8c4e2
#b6c7d8e9
verified
—
Approval Chain
CIO and CISO have signed. The CCO signature is pending receipt of the vendor-SOC-2 refresh; the program owner has logged the override and the compensating-control narrative.
Chief Information OfficerM. AlvarezSigned 2026-04-17T14:08:11Z
Chief Information Security OfficerJ. ParkSigned 2026-04-17T14:18:42Z
Valentra Labs is led by operators who scaled Clearwater's healthcare cybersecurity business from roughly $4M to $47M+ ARR and earned a Best in KLAS designation — cited operator history, not a customer-logo wall, carries the Day-1 trust.